EVAMIST (estradiol) by Design Pharmaceuticals is estrogen receptor agonists [moa]. First approved in 2007.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
EVAMIST is a transdermal spray formulation of estradiol, a synthetic estrogen that acts as an estrogen receptor agonist. It is indicated for vasomotor symptoms associated with menopause. The drug delivers estradiol through the skin to replace declining hormone levels in menopausal women.
Product approaching loss of exclusivity with modest Medicare spending signals a declining commercial footprint and likely consolidation of the brand team.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on EVAMIST at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moEVAMIST currently has zero linked job openings, reflecting its mature lifecycle and approaching loss of exclusivity. Careers on this product focus on defending market share and managing the transition to generic competition rather than growth and innovation.